ABPM

Verizon Business’ customer program wins big at the 2024 ABPM World Class Awards

Retrieved on: 
Tuesday, April 2, 2024
Verizon Business, ABPM, VZ, Verizon Communications, RSS

“Achieving World Class recognition in all four categories of ABPM’s World Class awards is an exceptionally difficult thing to do considering the high bar this community sets for ‘World Class’ designation.

Key Points: 
  • “Achieving World Class recognition in all four categories of ABPM’s World Class awards is an exceptionally difficult thing to do considering the high bar this community sets for ‘World Class’ designation.
  • Verizon Business demonstrated strength across categories – program, center, and an additional innovation award, which is an award given at juror discretion.
  • All of this is evidence of their exacting standards as well as the breadth of their services,” said Elizabeth Simpson, President, ABPM.
  • Headquartered in New York City and with a presence around the world, Verizon generated revenues of $134.0 billion in 2023.

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Ambulatory Blood Pressure Monitoring Devices Market Analysis Report 2024: A USD 1.87 Billion Market by 2030, Expanding at a CAGR of 8.4% from 2024 to 2030

Retrieved on: 
Thursday, March 14, 2024
Blood pressure, Stroke, Disability, Cardiovascular disease, Hypertension, Growth, Prevalence, Ageing, Death, Instrument, ABPM, Statistics, Data collection, WHO, Moyamoya disease, USD, Pharmaceutical industry

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Ambulatory Blood Pressure Monitoring Devices Market Size, Share & Trends Analysis Report By Product (Ambulatory Blood Pressure Monitors, Instrument & Accessories), By Type (Blood Pressure Cuffs, Others), By End-use, By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 14, 2024 /PRNewswire/ -- The "Ambulatory Blood Pressure Monitoring Devices Market Size, Share & Trends Analysis Report By Product (Ambulatory Blood Pressure Monitors, Instrument & Accessories), By Type (Blood Pressure Cuffs, Others), By End-use, By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global ambulatory blood pressure monitoring devices market size is expected to reach USD 1.87 billion by 2030, expanding at a CAGR of 8.45% from 2024 to 2030.
  • In addition, high blood pressure is a major risk factor for hemorrhagic stroke and coronary heart disease in this decade.
  • Also, technological advancement in ambulatory blood pressure monitoring (ABPM) devices is likely to boost the market over the forecast period.

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Blood pressure, DBP, Amlodipine, Roche, Month, Safety, Glomerular filtration rate, ABPM, Trial of the century, Cardiology, Indapamide, AGT, Hypertension, American College, SBP, EGFR, Patient, Angiotensin, DB, Alnylam Pharmaceuticals, Medication, RNA interference, Pharmaceutical industry

Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.

Key Points: 
  • Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
  • “We are thrilled that a single dose of zilebesiran achieved clinically significant, additional reductions in systolic blood pressure when administered to patients who are not adequately controlled with commonly prescribed antihypertensives,” said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam.
  • “These KARDIA-2 results, showing durable additional levels of blood pressure reduction on top of what is achieved by standard of care first-line antihypertensives with an encouraging safety profile, reinforce our confidence in zilebesiran’s differentiated profile.
  • The primary endpoint is the change from baseline in mean SBP at Month 3, assessed by 24-hour ABPM.

Sky Labs' CART BP Becomes the World's First to Complete Comparative Studies with All Blood Pressure Measurement Methods

Retrieved on: 
Wednesday, February 14, 2024
Blood pressure, CE, Hospital, Multimedia, US FDA, ABPM, Scientific Reports, KCJ, Seoul National University Hospital, Journal, CART, Research, Medical device

SEOUL, South Korea, Feb. 14, 2024 /PRNewswire/ -- CART BP is a ring-type 24/7 blood pressure monitor of the global healthcare startup Sky Labs(CEO Jack, Lee), and has fully established itself as the only ring-type wearable medical device to complete comparative studies with all blood pressure measurement methods, becoming the first in the world.  

Key Points: 
  • There are currently three main blood pressure measurement methods: auscultatory method in which a cuff-based blood pressure monitor and stethoscope are used in clinics to measure blood pressure; invasive blood pressure measurement method in which a needle or catheter is inserted into an artery (A-line) to measure intra-arterial pressure; and Ambulatory Blood Pressure Monitoring (ABPM) that measures blood pressure during a 24-hour period outside clinics by attaching a cuff and monitor to the body.
  • To prove CART BP's effectiveness, Sky Labs completed all comparative studies with these three blood pressure measurement methods.
  • In addition, Sky Labs validated accuracy in comparative studies with the invasive arterial blood pressure measurement method and standard stethoscopy.
  • CART BP is highly useful compared to other blood pressure monitors in that it enables 24-hour measurements of even blood pressure variability when an individual is asleep, not to mention awake.

Sky Labs' CART BP Becomes the World's First to Complete Comparative Studies with All Blood Pressure Measurement Methods

Retrieved on: 
Wednesday, February 14, 2024
Blood pressure, CE, Hospital, US FDA, ABPM, Scientific Reports, KCJ, Seoul National University Hospital, Journal, CART, Research, Medical device

SEOUL, South Korea, Feb. 14, 2024 /PRNewswire/ -- CART BP is a ring-type 24/7 blood pressure monitor of the global healthcare startup Sky Labs(CEO Jack, Lee), and has fully established itself as the only ring-type wearable medical device to complete comparative studies with all blood pressure measurement methods, becoming the first in the world.  

Key Points: 
  • There are currently three main blood pressure measurement methods: auscultatory method in which a cuff-based blood pressure monitor and stethoscope are used in clinics to measure blood pressure; invasive blood pressure measurement method in which a needle or catheter is inserted into an artery (A-line) to measure intra-arterial pressure; and Ambulatory Blood Pressure Monitoring (ABPM) that measures blood pressure during a 24-hour period outside clinics by attaching a cuff and monitor to the body.
  • To prove CART BP's effectiveness, Sky Labs completed all comparative studies with these three blood pressure measurement methods.
  • In addition, Sky Labs validated accuracy in comparative studies with the invasive arterial blood pressure measurement method and standard stethoscopy.
  • CART BP is highly useful compared to other blood pressure monitors in that it enables 24-hour measurements of even blood pressure variability when an individual is asleep, not to mention awake.

VIVUS Provides Update on Pipeline and Program Milestones

Retrieved on: 
Monday, January 8, 2024
Patient, Quality of life, HIV/AIDS, Bloating, Diarrhea, Inflammatory bowel disease, ABPM, Chronic pain, Enzyme replacement therapy, Cystic fibrosis, Heart, Degenerative disease, Exocrine pancreatic insufficiency, Comorbidity, Steatorrhea, Obesity, HIV, Amylase, Orthostatic hypertension, Phentermine, Heart failure, Exercise, Pharmaceutical industry

CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.

Key Points: 
  • CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.
  • “VIVUS has been continuously dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases, including exocrine pancreatic insufficiency, obesity and pulmonary arterial hypertension,” said John Amos, Chief Executive Officer at VIVUS LLC.
  • QSYMIA® is now the number one branded oral product in the US for obesity treatment.
  • Moreover, VIVUS is actively developing pipeline products focusing on bone marrow transplant preparation (VI-0609) and diabetes treatments (VI-0809 and VI-0810).”

New Clinical Data Demonstrate that QSYMIA®, the Leading Once-Daily Oral Weight-Management Medication, Reduces Blood Pressure

Retrieved on: 
Tuesday, November 28, 2023
Blood pressure, Dyslipidemia, Obstructive sleep apnea, ICER, Risk, Overweight, Physician, Principal, FDA, ABPM, Prevalence, Hypertension, Weight loss, Atherosclerosis, Mortality, Health, Ageing, Type, Obesity, Comorbidity, Type 2 diabetes, Patient, Safety, Cardiovascular disease, Phentermine, Hunger, Exercise

Obesity and high blood pressure are significant risk factors for the development of cardiovascular disease.

Key Points: 
  • Obesity and high blood pressure are significant risk factors for the development of cardiovascular disease.
  • “QSYMIA offers a differentiated profile consisting of demonstrated efficacy with respect to weight loss and blood pressure reduction, well-defined safety, convenient once-daily oral administration, and cost-effectiveness.
  • The once-daily pill is currently covered by the majority (81%) of commercial healthcare plans and is indicated for long-term use.
  • Importantly, obesity increases the risk of type 2 diabetes, hypertension and dyslipidemia, thereby increasing the risk of cardiovascular disease and mortality.

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Retrieved on: 
Saturday, November 11, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, AGT, Blood pressure, Hypertension, Safety, Month, RNA interference, AHA, Patient, American Heart Association, ABPM, Therapy, University, SBP, Female, Medication, Pharmaceutical industry

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of patients with hypertension and high cardiovascular risk.
  • The study results were presented during the American Heart Association (AHA) Scientific Sessions being held in Philadelphia, Pennsylvania from November 11-13, 2023.
  • The Company previously announced positive topline results from the KARDIA-1 study in September 2023.
  • The study also met key secondary endpoints across all doses, including demonstration of durable efficacy out to 6 months.

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Blood pressure, SBP, University, Therapy, American Heart Association, Serum, Roche, COVID-19, AGT, ISR, Medicine, Month, Arthralgia, Medication, Hypertension, Death, Injection site reaction, DB, ABPM, Arrest, Patient, Risk, Mercury (element), Alnylam Pharmaceuticals, RNA interference, Upper respiratory tract infection, Headache, Hyperkalemia, Safety, Pharmaceutical industry

The study results indicate zilebesiran was associated with dose-dependent, potent and durable knockdown of serum AGT levels through Month 6.

Key Points: 
  • The study results indicate zilebesiran was associated with dose-dependent, potent and durable knockdown of serum AGT levels through Month 6.
  • Zilebesiran also demonstrated an encouraging safety and tolerability profile that the company believes supports continued development.
  • These findings of robust and tonic blood pressure control will help determine the optimal dose and regimen of zilebesiran for future studies.
  • “Hypertension is a growing global health crisis responsible for around 10 million deaths worldwide each year.